Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Nano Lett ; 14(6): 3587-93, 2014 Jun 11.
Artigo em Inglês | MEDLINE | ID: mdl-24844116

RESUMO

Developing noninvasive and accurate diagnostics that are easily manufactured, robust, and reusable will provide monitoring of high-risk individuals in any clinical or point-of-care environment. We have developed a clinically relevant optical glucose nanosensor that can be reused at least 400 times without a compromise in accuracy. The use of a single 6 ns laser (λ = 532 nm, 200 mJ) pulse rapidly produced off-axis Bragg diffraction gratings consisting of ordered silver nanoparticles embedded within a phenylboronic acid-functionalized hydrogel. This sensor exhibited reversible large wavelength shifts and diffracted the spectrum of narrow-band light over the wavelength range λpeak ≈ 510-1100 nm. The experimental sensitivity of the sensor permits diagnosis of glucosuria in the urine samples of diabetic patients with an improved performance compared to commercial high-throughput urinalysis devices. The sensor response was achieved within 5 min, reset to baseline in ∼10 s. It is anticipated that this sensing platform will have implications for the development of reusable, equipment-free colorimetric point-of-care diagnostic devices for diabetes screening.

2.
J Environ Manage ; 131: 222-7, 2013 Dec 15.
Artigo em Inglês | MEDLINE | ID: mdl-24178315

RESUMO

This study investigated the adsorption behavior of the herbicides diquat, difenzoquat and clomazone on biopolymer membranes prepared with alginate and chitosan (pristine and multi-layer model) for contaminated water remediation applications. Herbicides, at concentrations ranging from 5 µM to 200 µM, were adsorbed in either pure alginate, pure chitosan or a bilayer membrane composed of chitosan/alginate. No adsorption of clomazone was observed on any of the membranes, probably due to lack of electrostatic interactions between the herbicide and the membranes. Diquat and difenzoquat were only adsorbed on the alginate and chitosan/alginate membranes, indicating that this adsorption takes place in the alginate layer. At a concentration of 50 µM, diquat adsorption reaches ca. 95% after 120 min on both the alginate and chitosan/alginate membranes. The adsorption of difenzoquat, at the same concentration, reaches ca. 62% after 120 min on pure alginate membranes and ca. 12% on chitosan/alginate bilayer membranes. The adsorption isotherms for diquat and difenzoquat were further evaluated using the isotherm models proposed by Langmuir and by Freundlich, where the latter represented the best-fit model. Results indicate that adsorption occurs via coulombic interactions between the herbicides and alginate and is strongly related to the electrostatic charge, partition coefficients and dissociation constants of the herbicides. Biopolymer based membranes present novel systems for the removal of herbicides from contaminated water sources and hold great promise in the field of environmental science and engineering.


Assuntos
Alginatos/química , Biopolímeros/química , Quitosana/química , Herbicidas/metabolismo , Poluentes Químicos da Água/metabolismo , Adsorção , Ácido Glucurônico/química , Ácidos Hexurônicos/química
4.
Lab Chip ; 14(5): 833-40, 2014 Mar 07.
Artigo em Inglês | MEDLINE | ID: mdl-24425070

RESUMO

The rapidly expanding number of mobile medical applications have the potential to transform the patient-healthcare provider relationship by improving the turnaround time and reducing costs. In September 2013, the U.S. Food and Drug Administration (FDA) issued guidance to regulate these applications and protect consumers by minimising the risks associated with their unintended use. This guidance distinguishes between the subset of mobile medical apps which may be subject to regulation and those that are not. The marketing claims of the application determine the intent. Areas of concern include compliance with regular updates of the operating systems and of the mobile medical apps themselves. In this article, we explain the essence of this FDA guidance by providing examples and evaluating the impact on academia, industry and other key stakeholders, such as patients and clinicians. Our assessment indicates that awareness and incorporation of the guidelines into product development can hasten the commercialisation and market entry process. Furthermore, potential obstacles have been discussed and directions for future development suggested.


Assuntos
Regulamentação Governamental , Aplicativos Móveis/normas , Guias como Assunto , Humanos , Internet , Sistemas Computadorizados de Registros Médicos/normas , Aplicativos Móveis/economia , Pacientes/psicologia , Médicos/psicologia , Medição de Risco , Software
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA